All Research Grants

Since 2001, Accelerate Brain Cancer Cure has provided more than $7 million in research funding to highly qualified research investigators and physician-scientists from 22 institutions.

University of California, Los Angeles
A genome-wide view of mTOR dependence in GBM.

Johns Hopkins University
Anti-excitotoxic therapies to target glioma growth.

Mayo Clinic
Cadherins and catenins as biomarkers of pediatric and adult glioma aggressiveness.

Memorial Sloan-Kettering Cancer Center
Cancer stem cells in gliomas

The Burnham Institute
Chemical inhibitors of XIAP for glioblastoma therapy.

University of California, San Francisco
Convection-enhanced delivery (CED) of immunoliposomes (ILs) in the monkey brain.

University of California, San Francisco
Convection-enhanced delivery of liposomes into brain tumors using real time MRI.

Johns Hopkins University
Depleting Cancer Stem Cells by Notch Pathway Blockade in Glioblastomas

University of California, Los Angeles
Developing biomarkers for oncogenic EGFR signaling in glioblastoma.

Duke University
Development of a clinical dendritic cell vaccine targeting human cytomegalovirus antigens expressed within high-grade malignant astrocytomas.

Duke University
Development of a clinical vaccine - in vitro assessment of immunologic relevance of over-expressed genes.

University of California, Los Angeles
Development of a microPLC for molecular diagnosis of glioblastoma.

The Wistar Institute
Development of MicroRNA Inhibitors for the Treatment of Glioblastomas

The Salk Institute for Biological Studies
Development of molecular targeted therapeutics for brain cancer. / Novel therapies for glioblastomas.

University of California, San Francisco
Development of novel targeted therapeutics for brain tumor treatment using immunoliposomes.

MD Anderson and Duke University
Development of potential synergistic therapies with small molecule inhibitors of receptor tyrosine kinases, intracellular elements and cytotoxic therapies.

University of California, Los Angeles
Development of targeted therapy for glioblastoma multiforme.

Memorial Sloan-Kettering Cancer Center
Development of therapeutic strategies for the inhibition of PI3K/AKT kinase-mediated signaling pathways in glioblastoma

Columbia University New York, NY
Directed evolution of cell penetrating peptides for therapeutic delivery across the blood-brain barrier to specific cellular targets.

Case Western University
Efficacy of PPARg agonists in treatment of glioma.

University of California, San Francisco
EGFRvIII-induced glioma and inhibitor-based treatment models

University of Alabama
Enhancement of glioma radiation therapy and chemotherapy with targeted antibody therapy against death receptor 5.

University of Texas/MD Anderson Cancer Center
Evaluation of small molecule inhibitors of the PI3K/AKT pathway

University of California, San Francisco
Evaluation of SNPs for whole genome scans in relation to glioma prognosis

University of California, San Francisco
Evolution of a hypomethylated and hyperproliferative phenotype in GBM and its reversal by a high mehtylation diet.

University of Southern California
Flouting COX-2: applying the COX-2-independent anti-tumor efficacy of Celebrex to the therapy of glioblastoma

University of Texas/MD Anderson Cancer Center
Gauging impact of treatment on symptoms, health-related quality of life, and neurocognitive function in patients with primary brain tumors.

Cedars-Sinai Medical Center
Gene profiling of human glial tumors.

ArmaGen Technologies
Genetic engineering of a recombinant neuroprotective neurotrophin that crosses the blood-brain barrier.

The Burnham Institute
IAP antagonists for glioblastoma.

MD Anderson Cancer Center
Identification of compensatory molecular pathways using functional genomic and synthetic lethality screening in glioblastoma treated with PI3K inhibitors.

Memorial Sloan-Kettering Cancer Center
Identification of fusion kinases as potential therapeutic targets in malignant astrocytoma and oligodendroglioma including malignant glioma.

Mayo Clinic
Identification of predictive markers for the response to combined radiation/EGFR inhibitor therapy in malignant gliomas.

University of California, San Francisco
Identification of prognostic surrogate markers in malignant gliomas by quantitative magnetic resonance imaging.

Duke University
Inactivation of regulatory T-cells to enhance immunotherapy against cytomegalovirus antigens in glioblastoma multiforme.

Dana Farber Cancer Institute
Inhibition of ATM and CHK2 as treatment for glioblastoma multiformes.

University of California, San Francisco
Inhibitor of alphaV-integrins in the treatment of glioblastomas.

Dana-Farber Cancer Institute
Inhibitors of the Fanconi Anemia pathway as chemosensitizing agents for 1,3-bis(2-chloroethyl)-1-nitrosourea.

University of California, San Francisco
Intracranial microinfusion of a novel, mechanism-based drug combination in the treatment of advanced GBM.

Institute of Cancer Research
Mechanism of novel phosphatidylinositol 3-kinase for use in glioblastoma therapy

University of California
Microarray analysis of glioblastoma: defining a fingerprint of PTEN loss for application to clinical trials.

Duke University
Modeling and perfecting convection-enhanced delivery of an EGFR-specific immunotoxin for the treatment of malignant brain tumors.

Cedars-Sinai Medical Center
Modulation of blood-brain tumor barrier permeability in GBM xenografts model patients with brain metastases.

University of California, Los Angeles
Molecular analysis of glioblastoma for kinase inhibitor therapy.

University of Texas/MD Anderson Cancer Center
Multigene Predictors of Outcome in Glioblastoma.

University of California, San Francisco
Neuro-oncology fellowship / glioma immunology.

University of California, Los Angeles
New approach to gene therapy of brain cancer.

Duke University
Non-pathogenic poliovirus recombinants for the treatment of malignant gliomas.

University of California, Los Angeles
Non-viral polygenic gene therapy of brain cancer.

Dana-Farber Cancer Institute
Notch inhibition in malignant gliomas.

University of Texas/MD Anderson Cancer Center
Novel PTEN/PI3K pathway inhibitors for glioblastoma therapy

Duke University
Optimizing use of signal transduction inhibitors for treatment of malignant gliomas.

University of California, Los Angeles
Pathways profiling of glioblastoma: identification of molecular correlates of sensitivity to EGFR inhibitors.

Harvard, Massachusetts General Hospital
Preclinical efficacy toxicity evaluation of an intra-arterial oncolytic virus and transient immunosuppression.

MD Anderson Cancer Center
Preclinical testing of malignant glioma models for signal transduction inhibitors and cytotoxic agents.

Northwestern University
Predicting the Therapy Response of High-Grade Gliomas based on a Network of Endogenous Modulators of Nuclear Factor-kappaB.

University of Amsterdam
Protein kinase target profiling and ex vivo target validation to identify efficacious inhibitors for malignant glioma

Memorial Sloan-Kettering Cancer Center
Proteomic serum markers for gliomas.

Duke University
Rational selection of small molecule and immunotoxin therapy in malignant gliomas

University of Colorado Health Sciences Center
Refinement of a novel yeast-based brain tumor vaccine.

Duke University Medical Center
RNA loaded dendritic cell vaccines targeting brain tumor stem cells during hematopoietic recovery from temozolomide-induced lymphopenia.

Stanford University
Sensitization of brain tumors to radiotherapy.

Mount Sinai Medical Center
Standardization of Perfusion MR Imaging and Predicting Clinical Outcome in Patients with Gliomas using Perfusion MR Metrics in a Multi-Institutional Setting.

Yale University
Targeting a glioma-specific isoform of BEHAB/Brevican for glioma therapy.

Duke University
Targeting DNA damage checkpoint signaling in glioma radioresistance.

Duke University
Targeting non-mitogenic receptor kinases and intracellular mediators in glioma therapy.

University of Colorado Health Sciences Center
The development of a novel brain tumor vaccine.

Dana-Farber Cancer Institute
Therapeutic use of CXCR4 antagonists in glioblastoma

Washington University
Transglutaminase 2 inhibitor, KC009, sensitizes glioblastomas to chemotherapy.